CD274 and neoplasm: Although the potential biomarkers for immunotherapy, including PD-L1 expression levels, tumor-infiltrating lymphocytes (TILs), and tumor mutation burden (TMB), have been investigated, none of them have shown a significant association with the intracranial response or prognosis (11–13).